Recombinant human

U.S.A., in lactating dairy cattie to increase milk production. EH Lilly and Company, The Upjohn Company, and American Cyanamid Company also have interests in the commercial appHcation of recombinant bovine GH. Recombinant porcine GH [9061-23-8] preparations from several companies, eg. The Upjohn Company, Smith Kline Beecham Animal Health, Pitman-Moore, Inc., Monsanto Company, and American Cyanamid Company, are being evaluated for commercial use. Recombinant human GH for clinical use is marketed under such names as Protropin (Genentech), Umatrope (EH Lilly), Genotropin (Sumitomo), and Somatonorm (Kabi-Vitmm) by a variety of pharmaceutical companies. A listing of additional suppHers is available (2). [Pg.176]

Interleukin-2 (recombinant human) [94218-72-1] Mr-15,000, amorphous. Purified by reverse phase HPLC. [Weir and Sparks Biochem J 245 85 1 987 Robb et al. Proc Natl Acad Sci USA 81 6486 1984.]... [Pg.544]

FIGURE 2.10 Analytical SEC for determination of abnegates in preparations of recombinant human growth hormone using Superdex 75 HR 10/30. [Reproduced from Hagel (1993). with permission.]... [Pg.54]

J. S. Pati ick and A. L. Lagu, Determination of recombinant human proinsulin fusion protein produced in Escherichia coli using oxidative sulfitolysis and two-dimensional HPLC, Chem. 64 507-511 (1992). [Pg.295]

Direct laser-assisted myocardial revascularization (DMR) is an approved technique in the US, Europe, and parts of Asia to create numerous myocardial channels. This results in the induction of a massive inflammatory reaction, which in turn induces angiogenesis. The other FDA-approved pro-angiogenic therapy is the use of recombinant human platelet-derived growth factor (Regranex) for use in the treatment of diabetic neuropathic foot ulcer s. [Pg.88]

Recombinant humanized monoclonal antibodies have been used recently to target antigens that are preferentially located on cancer cells. Examples include trastuzumab and rituximab which are used to treat HER2 positive breast cancer and B-cell type lymphomas, respectively. Unwanted side effects include anaphylactic reactions. [Pg.156]

Recombinant human DL-1 receptor antagonist (Anakinra, Kineret ) blocks the biological activity of interleukin-1 by competitively inhibiting IL-1 binding to the interleukin-1 type I receptor (IL-1RI), which is expressed in a wide variety of tissues and organs. Thereby it reduces the pro-inflammatory activities of IL-1 including cartilage destiuction and bone resorption. Side effects include an increased risk of infections and neutropenia. [Pg.412]

Erythropoietin is a growth factor produced by interstitial cells of the kidney in response to hypoxia. Erythropoietin stimulates haematopoiesis in the bone marrow. Recombinant human erythropoietin is used to treat anemias, e.g. anemia caused by chronic renal failure and anemia in AIDS and cancer patients. [Pg.483]

The use of recombinant hematopoietic growth factors (i.e., the commercially available forms of the native products) has been evaluated in many disorders affecting all types of blood cells. Recombinant human hematopoietic growth factors are identified as rHu. Not all uses discussed have received regulatory approval in all countries. [Pg.581]

Armitage JO (1998) Emerging applications of recombinant human granulocyte colony-stimulating factor. Blood 92 4491-4508... [Pg.581]

Bain VG, Kaita KD, Yoshida EM, Swain MG, Heathcote EJ, Neumann AU, FisceUa M, Yu R, Osborn BE, Cronin PW, Ereimuth WW, McHutchison JG, Subramanian GM (2006) A phase 2 study to evaluate the antiviral activity, safety, and pharmacokinetics of recombinant human albumin-interferon alfa fusion protein in genotype 1 chronic hepatitis C patients. J Hepatol 44 671-678... [Pg.230]

Balan V Nelson DR, Sulkowski MS, Everson GT, Lambiase LR, Wiesner RH, Dickson RC, Post AB, Redfleld RR, Davis GL, Neumann AU, Osborn BE, Ereimuth WW, Subramanian GM (2006) A Phase I/II study evaluating escalating doses of recombinant human albumin-interferon-alpha fusion protein in chronic hepatitis C patients who have failed previous interferon-alpha-based therapy, Antivir Ther 11 35 5... [Pg.230]

Hong SH, Cho O, Kim K, Shin HJ, Kotenko SV, Park S (2007) Effect of interferon-lambda on replication of hepatitis B virus in human hepatoma cells. Virus Res 126 245-249 Hoofnagle JH, Mullen KD, Jones DB, Rustgi V, Di BiscegUe A, Peters M, Waggoner JG, Park Y, Jones EA (1986) Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon. A preliminary report. N Engl J Med 315 1575-1578 Horiike N, Onji M (2003) Combination therapy with interferon-alpha and ribavirin as im-munomodulators in patients with chronic hepatitis C. J Gastroenterol 38 302-304... [Pg.234]

Rosina E, Pintus C, Meschievitz C, Rizzedo M (1991) A randomized controlled trial of a 12-month course of recombinant human interferon-alpha in chronic delta (type D) hepatitis a multicenter Italian study. Hepatology 13 1052-1056... [Pg.239]

Hertogs K, de Bethune MP, Miller V, Ivens T, Schel P, Van Cauwenberge A, Van Den Eynde C, Van Gerwen V, Azijn H, Van Houtte M, Peelers F, Staszewski S, Conant M, Bloor S, Kemp S, Larder B, Pauwels R (1998) A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency virus type 1 isolates from patients treated with antiretroviral drugs. Antimicrob Agents Chemother 42 269-276... [Pg.316]

Vrhovski, B., Jensen, S., and Weiss, A.S., Coacervation characteristics of recombinant human tropoelas-tin, Europ. J. Biochem., 250, 92-98 1997. [Pg.274]

Belhngham, C.M., Lillie, M.A., Gosline, J.M., Wright, G.M., Starcher, B.C., Bailey, A.J., Woodhouse, K.A., and Keeley, F.W., Recombinant human elastin polypeptides self-assemble into biomaterials with elastin-hke... [Pg.274]

Costa JJ, Demetri GD, Harris TJ. Dvorak AM. Hayes DF, Merica EA, Menchaca DM. Gringeri AJ. Schwartz LB, Galli SJ Recombinant human stem cell factor (kit ligand) promotes human mast cell and melanocyte hyperplasia and functional activation in vivo. J Exp Med 1996 183 2681-2686. [Pg.65]

Medvedev AE, Veselovsky AV, Shvedov VI, Tikhonova OV, Moskvitina TA, Fedotova OA, et al. Inhibition of monoamine oxidase by pirlindole analogues 3D-QSAR and CoMFA analysis. / Chem Inf Comput Sci 1998 38 1137-44. Miller JR, Edmondson DE. Structure-activity relationships in the oxidation of para-substituted benzylamine analogues by recombinant human liver monoamine oxidase A. Biochemistry 1999 38 13670-83. [Pg.466]

Irony-Tur-Sinai M, Grigoriadis N, Lourbopoulos A, Pinto-Maaravi F, Abramsky O, Brenner T (2006) Amelioration of autoimmune neuroinflammation by recombinant human alpha-fetoprotein. Exp Neurol 198 136-144... [Pg.140]

Papadopoulos SM, Chandler WF, Salamat MS, Topol EJ, Sackellares JC. Recombinant human tissue-type plasminogen activator therapy in acute thromboembolic stroke. J Neurosurg. 1987 67 394-398. [Pg.56]

If immune reactions are to be avoided then recombinant human factor should be used and that cannot be produced in large quantities. In any case, it is a large protein that will have to be injected directly into the brain. Even if these problems can be overcome the spread and intensity of any NGF effect has to be restricted so that excessive neuritic growth and inappropriate increases in synaptic connections do not occur. [Pg.391]

Lindqvist, A. and Andersson, S., Biochemical properties of purified recombinant human beta-carotene 15,15-monooxygenase, J. Biol. Chem., 277, 23942, 2002. Krinsky, N.I., Cornwell, D.G., and Oncley, J.I., The transport of vitamin A and carotenoids in human plasma. Arch. Biochem. Biophys., 73, 233, 1958. [Pg.174]

Zimmerman, RJ., Chan, A. and Leadon, S.A. (1989). Oxidative damage in murine tumour cells treated in vitro by recombinant human tumour necrosis factor. Cancer Res. 49, 1644-1648. [Pg.214]

RGD Arginine-glycine-asparagine rh- Recombinant human - (prefix usually referring to peptides)... [Pg.286]

Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...